Immunotherapy in Waldenstrom’s Macroglobulinemia
- 7 October 2016
- book chapter
- other
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- How to manage Waldenstrom’s macroglobulinemiaLeukemia, 2013
- Neutropenia after rituximab treatmentCurrent Opinion in Hematology, 2012
- Late-Onset Neutropenia After Rituximab TreatmentMedicine, 2010
- Extended rituximab therapy in Waldenström's macroglobulinemiaAnnals of Oncology, 2005
- Initial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemiaCancer, 2004
- Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98)Leukemia & Lymphoma, 2004
- Treatment of Waldenström’s Macroglobulinemia With RituximabJournal of Clinical Oncology, 2002
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s MacroglobulinemiaJournal of Immunotherapy, 2001